167 related articles for article (PubMed ID: 22224867)
1. Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?
Rudzki Z; Giles L; Cross NC; Lumley M
Br J Haematol; 2012 Mar; 156(5):558. PubMed ID: 22224867
[No Abstract] [Full Text] [Related]
2. Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.
Chaudhary LN; Bailey NG; Vos JA; Stotler CJ
W V Med J; 2013; 109(2):6-9. PubMed ID: 23600098
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
4. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
Helbig G; Kyrcz-Krzemien S
Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
[No Abstract] [Full Text] [Related]
5. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
6. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
[TBL] [Abstract][Full Text] [Related]
7. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
von Bubnoff N; Sandherr M; Schlimok G; Andreesen R; Peschel C; Duyster J
Leukemia; 2005 Feb; 19(2):286-7. PubMed ID: 15618966
[No Abstract] [Full Text] [Related]
8. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Miyazawa K; Kakazu N; Ohyashiki K
Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
[TBL] [Abstract][Full Text] [Related]
10. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
Srinivasan A; Scordino T; Baker A
J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
[No Abstract] [Full Text] [Related]
11. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
12. Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFRα Mutation.
Bikhchandani M; Johnson R; Tuan B; Tefferi A
Acta Haematol; 2018; 140(2):67-70. PubMed ID: 30184522
[TBL] [Abstract][Full Text] [Related]
13. Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia.
Alrwas A; Quesada JR; Marcos LA; Mehta SS; Shattuck BL; Nguyen ND; Juneja HS
Cancer Genet; 2012 Oct; 205(10):519-22. PubMed ID: 22944561
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm.
Blum S; Dunet V; Comoli P; Tirefort Y; Chalandon Y; Opota O; Comte D; Spertini O; Livio F; Brouland JP; Du Pasquier R
Leuk Lymphoma; 2020 Sep; 61(9):2226-2229. PubMed ID: 32364409
[No Abstract] [Full Text] [Related]
15. Blood and Bone Marrow Evaluation for Eosinophilia.
Boyer DF
Arch Pathol Lab Med; 2016 Oct; 140(10):1060-7. PubMed ID: 27684977
[TBL] [Abstract][Full Text] [Related]
16. A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm.
Dalland JC; Blackburn PR; Reichard KK; Johnson SH; Smadbeck JB; Vasmatzis G; Hoppman NL; Xu X; Greipp PT; Baughn LB; Peterson JF
Lab Med; 2022 Sep; 53(5):e134-e138. PubMed ID: 35217871
[TBL] [Abstract][Full Text] [Related]
17. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene.
Sorour Y; Dalley CD; Snowden JA; Cross NC; Reilly JT
Br J Haematol; 2009 Jul; 146(2):225-7. PubMed ID: 19466970
[No Abstract] [Full Text] [Related]
19. Transient macular erythema with eosinophilia in a patient carrying the FIP1L1-PDGFRA fusion gene.
Yahara H; Satoh T; Hashimoto T; Yokozeki H
Br J Dermatol; 2007 Dec; 157(6):1284-7. PubMed ID: 17916194
[No Abstract] [Full Text] [Related]
20. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]